Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

🚨 DR. WILLIAM MAKIS SAYS THIS IS THE MOST IMPORTANT IVERMECTIN DOSING GRAPH HE'S CREATED. Not a new chemotherapy drug. Not a breakthrough immunotherapy. Not a billion-dollar cancer treatment. Just one simple dosing strategy. According to Dr. William Makis, this is the dosing framework he believes everyone researching repurposed...

rxmeds_store's profile picture

RXMEDS.STORE

6,150 subscribers

326,944 görüntüleme • 7 gün önce •via X (Twitter)

Bilim & TeknolojiSağlık & İyilikHaberler & Politika
LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses
1:59

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses

Dr. Zakaria MD

57,857 görüntüleme • 1 gün önce

🚨 DR. WILLIAM MAKIS’ IVERMECTIN DOSING GUIDE FOR CANCER & PREVENTION IS SPREADING FAST ONLINE Thousands are now discussing Dr. William Makis MD’s categorized Ivermectin dosing approach based on body weight (mg/kg/day) and cancer severity. Here’s the breakdown people keep sharing: LOW DOSE: ≤ 0.5 mg/kg/day Often discussed for: • Remission support • Prevention strategies • Strong family cancer history ⚠️ Reports shared online describe minimal long term side effects at lower ranges. Access them via PharmacyinUSA MEDIUM DOSE: 1.0 mg/kg/day Most commonly discussed for: • Breast cancer • Lung cancer • Colon cancer • Pancreatic cancer • Renal cancers ⚠️ Supporters claim this is the “standard starting range” used in many repurposed drug discussions. HIGH DOSE: 2.0 mg/kg/day Typically discussed for: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers ⚠️ Some anecdotal reports mention temporary visual side effects at higher dosing ranges. VERY HIGH DOSE: ≥ 2.5 mg/kg/day Usually discussed only for: • Advanced metastatic disease • Late stage aggressive cancers ⚠️ High dose use remains highly controversial and experimental. Quick weight example for a 60 kg (132 lb) adult: • Low: 30 mg/day • Medium: 60 mg/day • High: 120 mg/day • Very High: 150+ mg/day Why this conversation keeps exploding online: ✅ Ivermectin has decades of human use worldwide ✅ Growing interest in repurposed cancer drugs ✅ Observational and preclinical research continues expanding ✅ Patients are increasingly sharing personal experiences publicly. (Jase Medical) Still, millions are now asking why inexpensive repurposed drugs are generating so much public interest while receiving so little mainstream discussion. **The chart has been upscaled for better visibility** #Ivermectin #Fenbendazole #Mebendazole
5:52

🚨 DR. WILLIAM MAKIS’ IVERMECTIN DOSING GUIDE FOR CANCER & PREVENTION IS SPREADING FAST ONLINE Thousands are now discussing Dr. William Makis MD’s categorized Ivermectin dosing approach based on body weight (mg/kg/day) and cancer severity. Here’s the breakdown people keep sharing: LOW DOSE: ≤ 0.5 mg/kg/day Often discussed for: • Remission support • Prevention strategies • Strong family cancer history ⚠️ Reports shared online describe minimal long term side effects at lower ranges. Access them via PharmacyinUSA MEDIUM DOSE: 1.0 mg/kg/day Most commonly discussed for: • Breast cancer • Lung cancer • Colon cancer • Pancreatic cancer • Renal cancers ⚠️ Supporters claim this is the “standard starting range” used in many repurposed drug discussions. HIGH DOSE: 2.0 mg/kg/day Typically discussed for: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers ⚠️ Some anecdotal reports mention temporary visual side effects at higher dosing ranges. VERY HIGH DOSE: ≥ 2.5 mg/kg/day Usually discussed only for: • Advanced metastatic disease • Late stage aggressive cancers ⚠️ High dose use remains highly controversial and experimental. Quick weight example for a 60 kg (132 lb) adult: • Low: 30 mg/day • Medium: 60 mg/day • High: 120 mg/day • Very High: 150+ mg/day Why this conversation keeps exploding online: ✅ Ivermectin has decades of human use worldwide ✅ Growing interest in repurposed cancer drugs ✅ Observational and preclinical research continues expanding ✅ Patients are increasingly sharing personal experiences publicly. (Jase Medical) Still, millions are now asking why inexpensive repurposed drugs are generating so much public interest while receiving so little mainstream discussion. **The chart has been upscaled for better visibility** #Ivermectin #Fenbendazole #Mebendazole

PharmacyinUSA

90,785 görüntüleme • 2 ay önce

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .
1:00

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .

mcgill_medicines

96,306 görüntüleme • 2 gün önce

🚨 DR. WILLIAM MAKIS REVEALED THE IVERMECTIN DOSING STRATEGY HE'S USING IN CANCER PATIENTS. HERE'S WHAT HE'S SEEING. In a recent discussion, Dr. William Makis was asked a question many cancer patients are now researching: 📌 How does he use Ivermectin in cancer protocols? His answer surprised a lot of people. For most intermediate to high-grade cancers, Dr. Makis said his typical starting dose is: 💊 1 mg/kg per day For a 60 kg (132 lb) person, that's approximately: 📊 60mg daily According to him, that's roughly 5 times higher than the dose commonly used for parasitic infections. For lower-grade cancers, he often starts lower: 💊 0.5 mg/kg per day Examples discussed included: • Chronic Lymphocytic Leukemia (CLL) • Multiple Myeloma For a 60 kg person, that would be about: 📊 30mg daily And unlike many protocols circulating online, he noted that the dosing is typically: 📅 7 days per week But the dosage wasn't the part that got my attention. The timeline was. According to Dr. Makis, some patients may begin seeing changes in cancer markers within: ⏳ 3 to 4 weeks He specifically mentioned markers such as: 📉 PSA 📉 CEA 📉 CA-125 📉 Other cancer-related markers He explained that these markers can sometimes provide an early indication that something is changing before tumors physically shrink. Then come the scans. According to his experience: 📊 PET scans may begin showing reduced cancer activity within about a month. 📊 Physical tumor shrinkage often becomes visible after roughly 2 to 3 months on PET-CT, CT, or MRI imaging. That's why he generally recommends giving a protocol: ⏳ A full 3 months Before evaluating whether a meaningful response is occurring. But perhaps the most surprising statement came near the end. Dr. Makis said the best results he has personally seen were not necessarily from Ivermectin alone. According to him, some of the most dramatic responses occurred when patients combined: 💊 Ivermectin PLUS 💊 Chemotherapy That observation is likely to spark debate from every side of the conversation. Whether you agree with his conclusions or not, one thing is clear: More patients are reading studies. More doctors are discussing repurposed medicines. And more people are asking questions that weren't being asked a few years ago. That's why conversations around Ivermectin continue to grow across cancer communities worldwide. 🌐 Looking for Ivermectin, Fenbendazole, or Mebendazole? Explore RXMEDS.STORE. #Ivermectin #WilliamMakis #CancerResearch #CancerProtocol #RepurposedDrugs
3:34

🚨 DR. WILLIAM MAKIS REVEALED THE IVERMECTIN DOSING STRATEGY HE'S USING IN CANCER PATIENTS. HERE'S WHAT HE'S SEEING. In a recent discussion, Dr. William Makis was asked a question many cancer patients are now researching: 📌 How does he use Ivermectin in cancer protocols? His answer surprised a lot of people. For most intermediate to high-grade cancers, Dr. Makis said his typical starting dose is: 💊 1 mg/kg per day For a 60 kg (132 lb) person, that's approximately: 📊 60mg daily According to him, that's roughly 5 times higher than the dose commonly used for parasitic infections. For lower-grade cancers, he often starts lower: 💊 0.5 mg/kg per day Examples discussed included: • Chronic Lymphocytic Leukemia (CLL) • Multiple Myeloma For a 60 kg person, that would be about: 📊 30mg daily And unlike many protocols circulating online, he noted that the dosing is typically: 📅 7 days per week But the dosage wasn't the part that got my attention. The timeline was. According to Dr. Makis, some patients may begin seeing changes in cancer markers within: ⏳ 3 to 4 weeks He specifically mentioned markers such as: 📉 PSA 📉 CEA 📉 CA-125 📉 Other cancer-related markers He explained that these markers can sometimes provide an early indication that something is changing before tumors physically shrink. Then come the scans. According to his experience: 📊 PET scans may begin showing reduced cancer activity within about a month. 📊 Physical tumor shrinkage often becomes visible after roughly 2 to 3 months on PET-CT, CT, or MRI imaging. That's why he generally recommends giving a protocol: ⏳ A full 3 months Before evaluating whether a meaningful response is occurring. But perhaps the most surprising statement came near the end. Dr. Makis said the best results he has personally seen were not necessarily from Ivermectin alone. According to him, some of the most dramatic responses occurred when patients combined: 💊 Ivermectin PLUS 💊 Chemotherapy That observation is likely to spark debate from every side of the conversation. Whether you agree with his conclusions or not, one thing is clear: More patients are reading studies. More doctors are discussing repurposed medicines. And more people are asking questions that weren't being asked a few years ago. That's why conversations around Ivermectin continue to grow across cancer communities worldwide. 🌐 Looking for Ivermectin, Fenbendazole, or Mebendazole? Explore RXMEDS.STORE. #Ivermectin #WilliamMakis #CancerResearch #CancerProtocol #RepurposedDrugs

RXMEDS.STORE

36,906 görüntüleme • 1 ay önce

Ivermectin & Fenbendazole Cancer Secrets Revealed w/ Dr. William Makis Remarkable success stories are pouring in from people using Ivermectin and Fenbendazole to combat cancer. Mel Gibson dropped a bombshell on Joe Rogan’s podcast, revealing that three of his friends had “stage four cancer,” and now “all three of them don’t have cancer right now at all.” “And they had some serious stuff going on,” Gibson emphasized. Dr. William Makis, who treated one of Gibson’s friends, has been rigorously researching the anti-cancer potential of Ivermectin and Fenbendazole over the past two years. During that time, he discovered, “There are over 100 papers on the success of Ivermectin and cancer.” “Ivermectin can actually kill cancer stem cells,” Dr. Makis explained, noting that it targets the cells “that chemo can’t kill.” He added, “It can also reverse resistance that cancer cells develop to certain types of chemotherapy.” The benefits extend further. “It [Ivermectin] makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer,” he shared. Yet, research into these applications has been neglected. “Big Pharma has completely abandoned it. Ivermectin is off-patent. No one’s going to make money on it,” Dr. Makis pointed out. Taking action where others haven’t, Dr. Makis applied his findings to his practice. “I have over 1,000 cancer patients who are on either a combination of Ivermectin and Fenbendazole or Ivermectin and Mebendazole,” he shared. Some of his patients were “given a terminal diagnosis” but are now “cancer-free” or have their “cancer under control.” “Patients, for example, who are taking combinations of chemo and Ivermectin or radiation and Ivermectin are seeing dramatic results that oncologists have never seen, that radiation oncologists have never seen,” Dr. Makis shared. “Tumors shrinking down to almost nothing, liver metastases disappearing, brain metastases disappearing.” “There are hundreds, if not thousands, of testimonials” documenting the success stories of Ivermectin and Fenbendazole, Dr. Makis added, offering hope to patients seeking alternatives. He strongly believes that “the future of cancer care is in repurposed drugs.” For more information on the use of Ivermectin and Fenbendazole for cancer, follow Dr. William Makis (MakisMD) on 𝕏. --> MakisMD (See 9 More Revealing Stories Below)
22:06

Ivermectin & Fenbendazole Cancer Secrets Revealed w/ Dr. William Makis Remarkable success stories are pouring in from people using Ivermectin and Fenbendazole to combat cancer. Mel Gibson dropped a bombshell on Joe Rogan’s podcast, revealing that three of his friends had “stage four cancer,” and now “all three of them don’t have cancer right now at all.” “And they had some serious stuff going on,” Gibson emphasized. Dr. William Makis, who treated one of Gibson’s friends, has been rigorously researching the anti-cancer potential of Ivermectin and Fenbendazole over the past two years. During that time, he discovered, “There are over 100 papers on the success of Ivermectin and cancer.” “Ivermectin can actually kill cancer stem cells,” Dr. Makis explained, noting that it targets the cells “that chemo can’t kill.” He added, “It can also reverse resistance that cancer cells develop to certain types of chemotherapy.” The benefits extend further. “It [Ivermectin] makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer,” he shared. Yet, research into these applications has been neglected. “Big Pharma has completely abandoned it. Ivermectin is off-patent. No one’s going to make money on it,” Dr. Makis pointed out. Taking action where others haven’t, Dr. Makis applied his findings to his practice. “I have over 1,000 cancer patients who are on either a combination of Ivermectin and Fenbendazole or Ivermectin and Mebendazole,” he shared. Some of his patients were “given a terminal diagnosis” but are now “cancer-free” or have their “cancer under control.” “Patients, for example, who are taking combinations of chemo and Ivermectin or radiation and Ivermectin are seeing dramatic results that oncologists have never seen, that radiation oncologists have never seen,” Dr. Makis shared. “Tumors shrinking down to almost nothing, liver metastases disappearing, brain metastases disappearing.” “There are hundreds, if not thousands, of testimonials” documenting the success stories of Ivermectin and Fenbendazole, Dr. Makis added, offering hope to patients seeking alternatives. He strongly believes that “the future of cancer care is in repurposed drugs.” For more information on the use of Ivermectin and Fenbendazole for cancer, follow Dr. William Makis (MakisMD) on 𝕏. --> MakisMD (See 9 More Revealing Stories Below)

The Vigilant Fox 🦊

1,292,608 görüntüleme • 1 yıl önce

According to Dr. William Makis, high-dose ivermectin shows tremendous promise for treating a majority of cancers. The required dose is significant – about 1mg/kg, or 60mg daily for a 60kg person – far higher than what was discussed for COVID-19. So why isn't this being rushed into clinical trials? The answer, Dr. Makis reveals, is a story of profit over patients. Ivermectin is off-patent. No pharmaceutical company can monopolize profits from it, so they have no incentive to fund research. In a stunning revelation, Dr. Makis connects the dots: Merck, the original patent holder, actively badmouthed ivermectin during COVID. The reason? They are in a 50-50 partnership with Moderna on a new mRNA cancer vaccine. Pushing a cheap, generic cure would directly threaten their future billion-dollar profits. But the story doesn't end there. Dr. Makis also highlights the power of repurposed anti-parasitics like fenbendazole and its FDA-approved human version, mebendazole. These drugs work by upregulating p53, a critical tumor suppressor protein. This is crucial because emerging research suggests the COVID-19 vaccine spike protein may downregulate p53, a potential mechanism for the turbo-cancers being observed. Treatments like mebendazole offer a direct counter to this effect, something conventional chemo and radiation do not. The solution? Dr. Makis advocates for public policy that directs government cancer funding toward off-patent, repurposed drugs. This takes the politics and profiteering out of the equation, allowing science to focus on what truly matters: saving lives.
4:01

According to Dr. William Makis, high-dose ivermectin shows tremendous promise for treating a majority of cancers. The required dose is significant – about 1mg/kg, or 60mg daily for a 60kg person – far higher than what was discussed for COVID-19. So why isn't this being rushed into clinical trials? The answer, Dr. Makis reveals, is a story of profit over patients. Ivermectin is off-patent. No pharmaceutical company can monopolize profits from it, so they have no incentive to fund research. In a stunning revelation, Dr. Makis connects the dots: Merck, the original patent holder, actively badmouthed ivermectin during COVID. The reason? They are in a 50-50 partnership with Moderna on a new mRNA cancer vaccine. Pushing a cheap, generic cure would directly threaten their future billion-dollar profits. But the story doesn't end there. Dr. Makis also highlights the power of repurposed anti-parasitics like fenbendazole and its FDA-approved human version, mebendazole. These drugs work by upregulating p53, a critical tumor suppressor protein. This is crucial because emerging research suggests the COVID-19 vaccine spike protein may downregulate p53, a potential mechanism for the turbo-cancers being observed. Treatments like mebendazole offer a direct counter to this effect, something conventional chemo and radiation do not. The solution? Dr. Makis advocates for public policy that directs government cancer funding toward off-patent, repurposed drugs. This takes the politics and profiteering out of the equation, allowing science to focus on what truly matters: saving lives.

Camus

88,873 görüntüleme • 8 ay önce

🚨Ivermectin dosage for Cancer by William Makis In this clip, William Makis walks through an academic discussion on how ivermectin is evaluated in cancer settings and what he watches for first. According to Dr. William Makis, that's often not what happens. He explains that when patients respond to ivermectin, the earliest signs can appear in blood markers long before CT scans or MRIs show visible changes. Those imaging changes may take weeks or even months to catch up. That delay can lead people to assume nothing is happening and stop too early. If you're researching ivermectin, fenbendazole, or mebendazole protocols, understanding how response is measured may be just as important as the protocol itself. For those looking for a trusted source, many people choose GENIX MEDS for ivermectin, fenbendazole, and mebendazole. We provide seamless worldwide delivery of them 🚚🌎 #Ivermectin #WilliamMakis #CancerResearch #CancerAwareness
3:33

🚨Ivermectin dosage for Cancer by William Makis In this clip, William Makis walks through an academic discussion on how ivermectin is evaluated in cancer settings and what he watches for first. According to Dr. William Makis, that's often not what happens. He explains that when patients respond to ivermectin, the earliest signs can appear in blood markers long before CT scans or MRIs show visible changes. Those imaging changes may take weeks or even months to catch up. That delay can lead people to assume nothing is happening and stop too early. If you're researching ivermectin, fenbendazole, or mebendazole protocols, understanding how response is measured may be just as important as the protocol itself. For those looking for a trusted source, many people choose GENIX MEDS for ivermectin, fenbendazole, and mebendazole. We provide seamless worldwide delivery of them 🚚🌎 #Ivermectin #WilliamMakis #CancerResearch #CancerAwareness

GENIX MEDS

11,857 görüntüleme • 1 ay önce

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."
1:59

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Sense Receptor

227,993 görüntüleme • 8 ay önce

Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."
4:27

Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."

Sense Receptor

96,616 görüntüleme • 8 ay önce

🚨 DR. ANTONIO JIMENEZ ON NATURAL APPROACHES TO CANCER Dr. Antonio Jimenez, who runs clinics in Tijuana and Cancun, has been treating cancer patients naturally for over 35 years. He claims to have helped people with almost every type of cancer. One of the approaches he recommends is food-grade hydrogen peroxide taken orally. According to him, cancers are often linked to parasites or venoms, and hydrogen peroxide may help address both. He suggests starting with a low dose: Begin with 3 to 4 drops of 6% food-grade hydrogen peroxide in 6 to 8 ounces of water. Gradually increase the number of drops over time, up to around 20 drops per day. He references the book The One Minute Cure, which shares stories of people who reportedly overcame terminal cancers using this method. Whether you agree with this approach or not, one thing is clear. More practitioners and patients are exploring natural and alternative protocols for cancer, and these discussions are growing online. Visit PharmacyinUSA to access Ivermectin, Fenbendazole, and Mebendazole with worldwide delivery. #HydrogenPeroxide #Cancer #AlternativeHealth #Ivermectin
1:02

🚨 DR. ANTONIO JIMENEZ ON NATURAL APPROACHES TO CANCER Dr. Antonio Jimenez, who runs clinics in Tijuana and Cancun, has been treating cancer patients naturally for over 35 years. He claims to have helped people with almost every type of cancer. One of the approaches he recommends is food-grade hydrogen peroxide taken orally. According to him, cancers are often linked to parasites or venoms, and hydrogen peroxide may help address both. He suggests starting with a low dose: Begin with 3 to 4 drops of 6% food-grade hydrogen peroxide in 6 to 8 ounces of water. Gradually increase the number of drops over time, up to around 20 drops per day. He references the book The One Minute Cure, which shares stories of people who reportedly overcame terminal cancers using this method. Whether you agree with this approach or not, one thing is clear. More practitioners and patients are exploring natural and alternative protocols for cancer, and these discussions are growing online. Visit PharmacyinUSA to access Ivermectin, Fenbendazole, and Mebendazole with worldwide delivery. #HydrogenPeroxide #Cancer #AlternativeHealth #Ivermectin

PharmacyinUSA

44,247 görüntüleme • 22 gün önce

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure
3:49

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Dr. Zakaria MD

46,422 görüntüleme • 14 gün önce

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." #Fenbendazole #Ivermectin #Cancercure
3:49

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." #Fenbendazole #Ivermectin #Cancercure

Joe Tippens

166,528 görüntüleme • 8 ay önce

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds
3:32

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds

RXMEDS.STORE

16,612 görüntüleme • 1 ay önce

Dr. William Makis Exposes the Cancer Industry's Suppression of Generic, Life-Saving Drugs For over 15 years, preclinical research has consistently pointed to a shocking truth: cheap, widely available generic drugs like Ivermectin and Mebendazole show significant promise in fighting cancer. Yet, as Dr. William Makis reveals, this breakthrough science is being systematically ignored and suppressed. Why? The answer lies not in medical efficacy, but in profit. As Dr. Makis explains, both Ivermectin and Mebendazole have been off-patent since the mid-1990s. They are inexpensive to manufacture and cannot generate the massive, recurring revenue streams that the cancer industry is built upon. A cure that costs pennies is a threat to a multi-billion dollar business model. This is not a conspiracy theory; it is a documented strategy. Dr. Makis points to the shocking 2021 action by Johns Hopkins University, which secured a patent on Mebendazole despite it being an existing, FDA-approved generic drug. This move is a classic tactic of "evergreening" – not to promote research for the public good, but to control and potentially stifle it. By patenting a known compound for a new use (cancer), they create a legal monopoly. The goal isn't to inform the world of a potential cure; it's to own it, control its narrative, and prevent widespread, low-cost investigation and use by independent physicians. Doctors have the right to prescribe FDA-approved drugs "off-label." The existence of a promising, low-cost option should be revolutionary news. Instead, as Dr. Makis attests, those who dare to discuss it face coordinated attacks and a wall of silence from institutions that prioritize profit over patients. The case is open and shut. The drugs are real. The science is there. The motive for suppression is glaringly obvious. It’s time to demand answers and prioritize patient lives over pharmaceutical patents.
1:21

Dr. William Makis Exposes the Cancer Industry's Suppression of Generic, Life-Saving Drugs For over 15 years, preclinical research has consistently pointed to a shocking truth: cheap, widely available generic drugs like Ivermectin and Mebendazole show significant promise in fighting cancer. Yet, as Dr. William Makis reveals, this breakthrough science is being systematically ignored and suppressed. Why? The answer lies not in medical efficacy, but in profit. As Dr. Makis explains, both Ivermectin and Mebendazole have been off-patent since the mid-1990s. They are inexpensive to manufacture and cannot generate the massive, recurring revenue streams that the cancer industry is built upon. A cure that costs pennies is a threat to a multi-billion dollar business model. This is not a conspiracy theory; it is a documented strategy. Dr. Makis points to the shocking 2021 action by Johns Hopkins University, which secured a patent on Mebendazole despite it being an existing, FDA-approved generic drug. This move is a classic tactic of "evergreening" – not to promote research for the public good, but to control and potentially stifle it. By patenting a known compound for a new use (cancer), they create a legal monopoly. The goal isn't to inform the world of a potential cure; it's to own it, control its narrative, and prevent widespread, low-cost investigation and use by independent physicians. Doctors have the right to prescribe FDA-approved drugs "off-label." The existence of a promising, low-cost option should be revolutionary news. Instead, as Dr. Makis attests, those who dare to discuss it face coordinated attacks and a wall of silence from institutions that prioritize profit over patients. The case is open and shut. The drugs are real. The science is there. The motive for suppression is glaringly obvious. It’s time to demand answers and prioritize patient lives over pharmaceutical patents.

Camus

11,864 görüntüleme • 11 ay önce

Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. But the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin has multiple anti-cancer effects. “There are at least nine perfectly defined cancer targets affected by ivermectin,” oncologist Dr. Alfonso Dueñas-González, told The Epoch Times. The news outlet reported: "It [ivermectin] has a broad impact on the immune system, increasing immune offense against cancers." "It also inhibits cancer cell cycles, helping prevent the formation of new cancer cells. The drug promotes the killing of cancer cells by inducing mitochondrial stress and prevents cancer survival by preventing new blood vessels, which transport energy and fuel to cancers, from forming near cancer cells." Dr. Kathleen Ruddy, a cancer surgeon, observed a resounding improvement in three patients under her consultation after they started using ivermectin with additional therapies. One patient, facing terminal stage 4 prostate cancer and given only three weeks to live after all treatments failed, began using ivermectin. Remarkably, within two months, his indicators of prostate cancer plummeted, and by six months, his cancer had significantly receded. Less than a year later, he was energetically dancing for four hours, three nights a week. This miraculous recovery was not isolated, as two more patients experienced similar outcomes. Dr. Ruddy, with over 30 years in cancer surgery, reflected on these cases, saying, “I’ve been a cancer surgeon for over 30 years. I’ve never seen anything like this in one patient—let alone three in a row.” Read the full report in the comment below:
3:07

Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. But the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin has multiple anti-cancer effects. “There are at least nine perfectly defined cancer targets affected by ivermectin,” oncologist Dr. Alfonso Dueñas-González, told The Epoch Times. The news outlet reported: "It [ivermectin] has a broad impact on the immune system, increasing immune offense against cancers." "It also inhibits cancer cell cycles, helping prevent the formation of new cancer cells. The drug promotes the killing of cancer cells by inducing mitochondrial stress and prevents cancer survival by preventing new blood vessels, which transport energy and fuel to cancers, from forming near cancer cells." Dr. Kathleen Ruddy, a cancer surgeon, observed a resounding improvement in three patients under her consultation after they started using ivermectin with additional therapies. One patient, facing terminal stage 4 prostate cancer and given only three weeks to live after all treatments failed, began using ivermectin. Remarkably, within two months, his indicators of prostate cancer plummeted, and by six months, his cancer had significantly receded. Less than a year later, he was energetically dancing for four hours, three nights a week. This miraculous recovery was not isolated, as two more patients experienced similar outcomes. Dr. Ruddy, with over 30 years in cancer surgery, reflected on these cases, saying, “I’ve been a cancer surgeon for over 30 years. I’ve never seen anything like this in one patient—let alone three in a row.” Read the full report in the comment below:

The Vigilant Fox 🦊

1,192,158 görüntüleme • 2 yıl önce

When I caught Covid, my friends rushed doses of Ivermectin to me — kicked Covid in 24 hours. Here’s a cancer surgeon revealing her discoveries about the impact of Ivermectin on CANCER… 9 min. must see: Also — Compelling Evidence for Ivermectin in Treating Covid: · Front Line COVID-19 Critical Care Alliance Review — This review, which summarized findings from 27 studies, concluded that ivermectin demonstrates a strong signal of therapeutic efficacy against COVID-19. This includes both prevention and treatment aspects. · Meta-Analysis on Ivermectin — A meta-analysis covering 96 studies and over 135,000 patients suggests that ivermectin has shown effectiveness in combating COVID-19. This analysis points towards ivermectin's role in reducing severity and improving health outcomes. · Antiviral Effect Study — A study aimed at assessing the antiviral effect of high-dose ivermectin found it to have an impact on viral load, suggesting its potential in reducing the severity of the disease by decreasing the viral replication. Evidence for Ivermectin in Treating Cancer as summarized by Dr. William Makis, Radiologist, Oncologist, Cancer Researcher. NEW ARTICLE: IVERMECTIN and Protocols for CANCER Ivermectin has a dozen anti-cancer mechanisms but they can be summarized into two main ones: 1. Inhibits cancer proliferation signaling pathways (Akt, mTOR, Wnt) 2. Inhibits Cancer Stem Cells IVERMECTIN will act against regular CANCER as well as Pfizer and Moderna COVID-19 mRNA Vaccine Induced TURBO CANCER (which is highly resistant to chemo) Here are recent studies on IVERMECTIN use in certain types of cancer: BLADDER CANCER - (2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage LUNG CANCER - (2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells GLIOMA - (2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma MULTIPLE MYELOMA - (2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma OVARIAN CANCER - (2023 Jawad et al) - Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells PROSTATE CANCER - (2022 Lu et al) - Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer COLON CANCER - (2022, Alghamdi et al) - Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats PANCREATIC CANCER - (2022 Lee et al) - Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction MELANOMA - (2022 Zhang et al) - Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis IVERMECTIN has proven anti-cancer activity against some 20 cancer types, although these are pre-clinical studies. We will never see clinical studies because Ivermectin is off patent and cheap. Merck, which used to have a patent on Ivermectin, has partnered with Moderna on mRNA Cancer Vaccines. IVERMECTIN is so safe, that in much of the civilized world, it is available over the counter, no prescription needed. Ivermectin is annually taken by close to 250 million people.
9:41

When I caught Covid, my friends rushed doses of Ivermectin to me — kicked Covid in 24 hours. Here’s a cancer surgeon revealing her discoveries about the impact of Ivermectin on CANCER… 9 min. must see: Also — Compelling Evidence for Ivermectin in Treating Covid: · Front Line COVID-19 Critical Care Alliance Review — This review, which summarized findings from 27 studies, concluded that ivermectin demonstrates a strong signal of therapeutic efficacy against COVID-19. This includes both prevention and treatment aspects. · Meta-Analysis on Ivermectin — A meta-analysis covering 96 studies and over 135,000 patients suggests that ivermectin has shown effectiveness in combating COVID-19. This analysis points towards ivermectin's role in reducing severity and improving health outcomes. · Antiviral Effect Study — A study aimed at assessing the antiviral effect of high-dose ivermectin found it to have an impact on viral load, suggesting its potential in reducing the severity of the disease by decreasing the viral replication. Evidence for Ivermectin in Treating Cancer as summarized by Dr. William Makis, Radiologist, Oncologist, Cancer Researcher. NEW ARTICLE: IVERMECTIN and Protocols for CANCER Ivermectin has a dozen anti-cancer mechanisms but they can be summarized into two main ones: 1. Inhibits cancer proliferation signaling pathways (Akt, mTOR, Wnt) 2. Inhibits Cancer Stem Cells IVERMECTIN will act against regular CANCER as well as Pfizer and Moderna COVID-19 mRNA Vaccine Induced TURBO CANCER (which is highly resistant to chemo) Here are recent studies on IVERMECTIN use in certain types of cancer: BLADDER CANCER - (2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage LUNG CANCER - (2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells GLIOMA - (2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma MULTIPLE MYELOMA - (2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma OVARIAN CANCER - (2023 Jawad et al) - Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells PROSTATE CANCER - (2022 Lu et al) - Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer COLON CANCER - (2022, Alghamdi et al) - Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats PANCREATIC CANCER - (2022 Lee et al) - Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction MELANOMA - (2022 Zhang et al) - Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis IVERMECTIN has proven anti-cancer activity against some 20 cancer types, although these are pre-clinical studies. We will never see clinical studies because Ivermectin is off patent and cheap. Merck, which used to have a patent on Ivermectin, has partnered with Moderna on mRNA Cancer Vaccines. IVERMECTIN is so safe, that in much of the civilized world, it is available over the counter, no prescription needed. Ivermectin is annually taken by close to 250 million people.

Bobby

160,026 görüntüleme • 1 yıl önce

7 Compelling Reasons Why Ivermectin Is a ‘Powerful Drug’ for Fighting Cancer Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. It is safer than Tylenol and brought river blindness to the brink of extinction, but the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin is not only an effective treatment for COVID-19, but it could also be a “powerful drug” for fighting cancer. Here are 7 reasons why. 1. Multiple Anti-Cancer Effects: Ivermectin impacts at least nine well-defined cancer targets, according to Dr. Alfonso Dueñas-González, an oncologist and senior researcher. He states, "There are at least nine perfectly defined cancer targets affected by ivermectin." 2. Enhances Effects of Chemotherapy and Radiation: Ivermectin not only targets tumor stem cells and promotes cancer cell death but also "enhances the effects of chemo and radiation therapy." This broad impact on the immune system increases the offense against cancers, making it a versatile adjunct to conventional treatments. 3. Inhibits Cancer Cell Cycles: The drug prevents the formation of new cancer cells by inhibiting cancer cell cycles and inducing mitochondrial stress, which leads to the killing of cancer cells. This mechanism is crucial for stopping the proliferation of cancerous cells. 4. Prevents Formation of New Blood Vessels Near Cancer Cells: Ivermectin prevents cancer survival by inhibiting the formation of new blood vessels that transport energy and fuel to cancers. This action starves the cancer cells, hindering their growth and spread. 5. Synergizes with Immunotherapy: Dr. Peter P. Lee, chair of immuno-oncology at the City of Hope, found that ivermectin could synergize with immune checkpoint inhibitor anti-PD1, enhancing the body's immune response to fight cancer. "What we’re learning is that ivermectin is going to be a very powerful drug in the context of really carefully developed immunotherapy combinations," he said. 6. Targets Cancer Stem Cells: Ivermectin preferentially targets cancer stem cells, which are a driver of cancer tumors and relapses. By focusing on these cells, ivermectin attacks the root of cancer's resilience and ability to recur. 7. The Curious Case of Rick Alderson: Mr. Alderson, a retired sawmill worker, “was a dead man walking” and given 6 months to live after his terminal colon cancer had metastasized and spread to his liver, where it had formed 25 distinct tumors. After starting ivermectin, Rick Alderson's carcinoembryonic antigen (CEA) levels, which are markers for tumor activity, dropped significantly from 1,498 ng/mL to 13.9 ng/mL in a matter of months. Of the 25 tumors in Mr. Alderson's liver, only three remained after his treatment with ivermectin and chemotherapy, indicating a substantial reduction in tumor burden. Mr. Alderson lived for two more years beyond his initial six-month prognosis, which his wife attributes to the use of ivermectin alongside chemotherapy.
3:43

7 Compelling Reasons Why Ivermectin Is a ‘Powerful Drug’ for Fighting Cancer Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. It is safer than Tylenol and brought river blindness to the brink of extinction, but the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin is not only an effective treatment for COVID-19, but it could also be a “powerful drug” for fighting cancer. Here are 7 reasons why. 1. Multiple Anti-Cancer Effects: Ivermectin impacts at least nine well-defined cancer targets, according to Dr. Alfonso Dueñas-González, an oncologist and senior researcher. He states, "There are at least nine perfectly defined cancer targets affected by ivermectin." 2. Enhances Effects of Chemotherapy and Radiation: Ivermectin not only targets tumor stem cells and promotes cancer cell death but also "enhances the effects of chemo and radiation therapy." This broad impact on the immune system increases the offense against cancers, making it a versatile adjunct to conventional treatments. 3. Inhibits Cancer Cell Cycles: The drug prevents the formation of new cancer cells by inhibiting cancer cell cycles and inducing mitochondrial stress, which leads to the killing of cancer cells. This mechanism is crucial for stopping the proliferation of cancerous cells. 4. Prevents Formation of New Blood Vessels Near Cancer Cells: Ivermectin prevents cancer survival by inhibiting the formation of new blood vessels that transport energy and fuel to cancers. This action starves the cancer cells, hindering their growth and spread. 5. Synergizes with Immunotherapy: Dr. Peter P. Lee, chair of immuno-oncology at the City of Hope, found that ivermectin could synergize with immune checkpoint inhibitor anti-PD1, enhancing the body's immune response to fight cancer. "What we’re learning is that ivermectin is going to be a very powerful drug in the context of really carefully developed immunotherapy combinations," he said. 6. Targets Cancer Stem Cells: Ivermectin preferentially targets cancer stem cells, which are a driver of cancer tumors and relapses. By focusing on these cells, ivermectin attacks the root of cancer's resilience and ability to recur. 7. The Curious Case of Rick Alderson: Mr. Alderson, a retired sawmill worker, “was a dead man walking” and given 6 months to live after his terminal colon cancer had metastasized and spread to his liver, where it had formed 25 distinct tumors. After starting ivermectin, Rick Alderson's carcinoembryonic antigen (CEA) levels, which are markers for tumor activity, dropped significantly from 1,498 ng/mL to 13.9 ng/mL in a matter of months. Of the 25 tumors in Mr. Alderson's liver, only three remained after his treatment with ivermectin and chemotherapy, indicating a substantial reduction in tumor burden. Mr. Alderson lived for two more years beyond his initial six-month prognosis, which his wife attributes to the use of ivermectin alongside chemotherapy.

The Vigilant Fox 🦊

532,851 görüntüleme • 2 yıl önce

REPORT: A declassified CIA document suggests a potential cure for cancer may have been hidden from the public for more than 60 years. The discovery is fueling a disturbing question: if this research showed promise in the early 1950s, why did it remain locked away in intelligence archives for decades? The document, written in February 1951 and later declassified in 2014, summarizes a Soviet scientific paper examining striking biochemical similarities between parasitic worms and cancerous tumors. Researchers reported that both thrived under similar metabolic conditions, surviving in low-oxygen environments and storing large reserves of glycogen. The report also described experiments showing certain anti-parasitic compounds appeared to affect tumors. One drug, Myracyl D, already used to treat bilharzia parasites, reportedly showed activity against malignant growths as well. The findings didn’t claim cancer is caused by parasites. But they raised a provocative possibility: drugs developed to kill parasites might also disrupt tumor growth. Today, some physicians are revisiting that idea. Dr. William Makis, who treats cancer patients with repurposed medications such as ivermectin and related compounds, says he has worked with thousands of patients using these experimental treatment protocols. Makis believes the potential of these drugs has been underestimated for years. “Cancer is no longer a death sentence.” So why did research like this sit in the shadows for so long? Don't miss ZeeeMediaOfficial's report: 👇
12:42

REPORT: A declassified CIA document suggests a potential cure for cancer may have been hidden from the public for more than 60 years. The discovery is fueling a disturbing question: if this research showed promise in the early 1950s, why did it remain locked away in intelligence archives for decades? The document, written in February 1951 and later declassified in 2014, summarizes a Soviet scientific paper examining striking biochemical similarities between parasitic worms and cancerous tumors. Researchers reported that both thrived under similar metabolic conditions, surviving in low-oxygen environments and storing large reserves of glycogen. The report also described experiments showing certain anti-parasitic compounds appeared to affect tumors. One drug, Myracyl D, already used to treat bilharzia parasites, reportedly showed activity against malignant growths as well. The findings didn’t claim cancer is caused by parasites. But they raised a provocative possibility: drugs developed to kill parasites might also disrupt tumor growth. Today, some physicians are revisiting that idea. Dr. William Makis, who treats cancer patients with repurposed medications such as ivermectin and related compounds, says he has worked with thousands of patients using these experimental treatment protocols. Makis believes the potential of these drugs has been underestimated for years. “Cancer is no longer a death sentence.” So why did research like this sit in the shadows for so long? Don't miss ZeeeMediaOfficial's report: 👇

The Vigilant Fox 🦊

196,881 görüntüleme • 4 ay önce

A stunning revelation from the front lines of medicine. Dr. William Makis is reporting unprecedented success using ivermectin for two of our most devastating neurological conditions: Parkinson's and Alzheimer's disease. His accidental discovery is yielding results that defy conventional expectations. For Parkinson's, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years. The outcomes in Alzheimer's are even more profound. Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles. Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically. The stories are heart-rending: "My grandma's back." Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile. Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer's appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug. He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore. The question remains: When the evidence is this compelling, and the reward is the reversal of human suffering, why isn't this being researched at the highest levels?
3:57

A stunning revelation from the front lines of medicine. Dr. William Makis is reporting unprecedented success using ivermectin for two of our most devastating neurological conditions: Parkinson's and Alzheimer's disease. His accidental discovery is yielding results that defy conventional expectations. For Parkinson's, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years. The outcomes in Alzheimer's are even more profound. Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles. Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically. The stories are heart-rending: "My grandma's back." Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile. Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer's appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug. He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore. The question remains: When the evidence is this compelling, and the reward is the reversal of human suffering, why isn't this being researched at the highest levels?

Camus

710,480 görüntüleme • 9 ay önce

Three Cancer Patients Defy Odds with Ivermectin: A Doctor’s Call for Urgent Research Dr. Kathleen Ruddy, a breast cancer surgeon, author, and inventor, shared remarkable stories of three patients with advanced, aggressive cancers who chose ivermectin based on their own research, yielding astonishing outcomes that raise urgent questions about repurposed drugs in oncology. The first, Paul Mann, a 53-year-old marathoner from Phoenix with no family history of cancer, was diagnosed with stage 4 prostate cancer two months after his second Pfizer vaccine. Given three weeks to live, with hospice called, Paul started ivermectin. Slowly, his condition improved; today, he dances four hours a night, three nights a week. His tumor hasn’t fully regressed, but he’s exploring other repurposed medications, a far cry from his initial prognosis. The second patient, Eddie, a man in his late 60s, had unresectable esophageal carcinoma with two inoperable tumors. Declining chemo and radiation, he took ivermectin alone. Within six weeks, his tumors vanished completely, with no other treatment. The third, a woman with an 18cm pelvic tumor originating from her stomach lining, faced grim odds. After a remarkable surgical resection, liver metastases remained. Post-op, she chose ivermectin, and her liver metastases cleared entirely. Dr. Ruddy cautions that three patients aren’t a clinical trial, but three consecutive, dramatic responses in such dire cases are striking. She believes “there’s something going on here that looks important.” Frustrated by the pharmaceutical industry’s disinterest, as well as the lack of support from academic institutions and philanthropies—none of whom she expects to fund ivermectin research due to its low cost—she’s strategizing a scientifically sound, ethical approach to study whether ivermectin and other repurposed drugs can improve cancer survival. These anecdotes aren’t definitive evidence but compel us to ask: could repurposed drugs hold untapped potential for cancer treatment? Rigorous research is needed to find out.
4:06

Three Cancer Patients Defy Odds with Ivermectin: A Doctor’s Call for Urgent Research Dr. Kathleen Ruddy, a breast cancer surgeon, author, and inventor, shared remarkable stories of three patients with advanced, aggressive cancers who chose ivermectin based on their own research, yielding astonishing outcomes that raise urgent questions about repurposed drugs in oncology. The first, Paul Mann, a 53-year-old marathoner from Phoenix with no family history of cancer, was diagnosed with stage 4 prostate cancer two months after his second Pfizer vaccine. Given three weeks to live, with hospice called, Paul started ivermectin. Slowly, his condition improved; today, he dances four hours a night, three nights a week. His tumor hasn’t fully regressed, but he’s exploring other repurposed medications, a far cry from his initial prognosis. The second patient, Eddie, a man in his late 60s, had unresectable esophageal carcinoma with two inoperable tumors. Declining chemo and radiation, he took ivermectin alone. Within six weeks, his tumors vanished completely, with no other treatment. The third, a woman with an 18cm pelvic tumor originating from her stomach lining, faced grim odds. After a remarkable surgical resection, liver metastases remained. Post-op, she chose ivermectin, and her liver metastases cleared entirely. Dr. Ruddy cautions that three patients aren’t a clinical trial, but three consecutive, dramatic responses in such dire cases are striking. She believes “there’s something going on here that looks important.” Frustrated by the pharmaceutical industry’s disinterest, as well as the lack of support from academic institutions and philanthropies—none of whom she expects to fund ivermectin research due to its low cost—she’s strategizing a scientifically sound, ethical approach to study whether ivermectin and other repurposed drugs can improve cancer survival. These anecdotes aren’t definitive evidence but compel us to ask: could repurposed drugs hold untapped potential for cancer treatment? Rigorous research is needed to find out.

Camus

38,022 görüntüleme • 1 yıl önce